FDA’s top gene therapy regulator is leaving his role
The FDA's top gene therapy regulator is stepping down, amid a significant setback for a kidney disease drug.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Vijay Kumar stepped down from his leadership role as the FDA's top gene and cell therapy regulator. He left the position after one year.
Epilogue added 14d ago, after coverage quieted.
The brief
The FDA's acting director of cell and gene therapies, Vijay Kumar, is leaving his role. Coverage emphasizes the departure of Kumar, who has been in the position for one year.
Coverage also highlights the FDA's decision to decline approval for Unicycive's kidney disease drug, leading to a significant drop in the company's stock. The news is covered by Reuters, Yahoo, BioSpace, Endpoints News, BioPharma Dive, Fierce Biotech, and statnews.com.
Watch for announcements regarding Kumar's next steps and the FDA's plans for filling the vacant role. Also, monitor Unicycive's response to the FDA's Complete Response Letter and the potential timeline for resubmission.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 20d ago.
Quick answers
Who is leaving the FDA?
Vijay Kumar, the acting director of cell and gene therapies, is stepping down from his role.
How long has Kumar been in his position?
Kumar has been in the position for one year.
What other significant events are occurring at the FDA?
The FDA has declined to approve Unicycive's kidney disease drug, leading to a plunge in the company's stock.
Coverage (9)
- Unicycive shares plunge after FDA issues Complete Response Letter for kidney disease drug (UNCY) Yahoo Finance · 21d ago
- US FDA declines to approve Unicycive's kidney disease drug Reuters · 21d ago
- UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval TradingView · 21d ago
- Top FDA gene and cell therapy regulator to step down Yahoo · 21d ago
- FDA’s cell and gene therapy head steps down after 1 year BioSpace · 21d ago
- FDA’s acting director of cell and gene therapies to leave position Endpoints News · 21d ago
- Top FDA gene and cell therapy regulator to step down BioPharma Dive · 21d ago
- FDA gene therapy regulator Vijay Kumar steps down from leadership role Fierce Biotech · 21d ago
- FDA’s top gene therapy regulator is leaving his role statnews.com · 21d ago
Topics
Related trends
Boston Children’s and the Broad Institute partner on new center for rare genetic diseases
Three major institutions have launched the Center for Therapeutic Genetics to develop medicines for rare and ultra-rare diseases.
Seattle breakthrough offers Spokane boy relief from rare hunger condition
A Spokane boy is finding relief from a rare hunger condition following a medical breakthrough in Seattle and new FDA approval for hypothalamic obesity.
FDA still focused on Taylor Farms lettuce as Cyclospora source despite retracted test
The FDA continues to target Taylor Farms as the source of a cyclosporiasis outbreak despite a retracted test result.
Alzheimer's: Real-world study confirms Leqembi therapy benefits
FDA approval of an at-home subcutaneous starter dose for Leqembi coincides with a real-world study confirming the therapy's benefits.
Explosive diarrhea outbreak: Lettuce tests positive for cyclospora, FDA says
A widespread Cyclospora parasite outbreak has triggered an iceberg lettuce recall across 27 US states, impacting major retailers and fast-food chains.
Taylor Farms lettuce sample tests positive for Cyclospora as recall expands
Taylor Farms has initiated a wide-reaching lettuce recall following a positive test for the parasite Cyclospora.